**COVID PHE Fact Sheet: COVID-19 Vaccines and Treatment**

**Updated: 7/26/2023**

**Overview**

COVID-19 vaccines and treatment updates

**What Health Centers Need to Know**

**Critical Points-COVID-19 Vaccines**

* **Commercialization of COVID-19 vaccines** **\*NEW\***
	+ HRSA and MDHHS COVID-19 vaccine ordering through the federal government will end August 3rd. Orders can be placed through MDHHS until August 3rd and through HRSA until August 23rd.
	+ Please review MCIR data (physical inventory and doses administered reports) to determine need for August and September. Do not overstock!
	+ New strain vaccines are expected to be available mid to late September 2023, these vaccines will be the first COVID-19 vaccines available through the manufacturers directly.
* **Vaccines for those who are uninsured/underinsured** **\*NEW\***
	+ Uninsured/underinsured/Medicaid-eligible children under the age of 19 will be able to receive vaccines from the VFC program
	+ Uninsured adults will be able to receive vaccines through a program called the Bridge Access Program.
	+ Vaccines for both programs will be ordered through MCIR/MDHHS
* Can health center be paid for the COVID-19 vaccines post PHE?
	+ The COVID-19 vaccines are supplied by the federal government at no cost to the health center thus the vaccine (medication) itself is no reimbursable. The only service that would be payable (by any payer) would be the administration of the COVID-19 vaccine.
	+ For Medicare, the COVID-19 vaccine administration is paid on the cost report.
	+ For Medicaid, health centers are eligible reimbursement for COVID-19 vaccine administration when no other qualifying visit is performed (at times referred to as a stand-alone COVID-19 vaccine administration) after the ending of the PHE. MDHHS did require all health centers to complete an APM agreement in order to be eligible for reimbursement. Health center will continue to be eligible for reimbursement (with the APM agreement on file) through September 30, 2024.
	+ For commercial insurance, many do and are expected to continue to reimburse providers for COVID-19 vaccine administration.
* Where can I find more information on billing and reimbursement for COVID-19 vaccines?
	+ MPCA has put together the  [COVID-19 Vaccine Info (05.01.2023)](https://nam04.safelinks.protection.outlook.com/ap/x-59584e83/?url=https%3A%2F%2Fmpcanet-my.sharepoint.com%2F%3Ax%3A%2Fg%2Fpersonal%2Fkfrazier_mpca_net%2FEcXiKFkiGm9PrLZ8SSL90j4BGvfZLVeWZLCcUDpXX8hvtg%3Fe%3DtDiAEE&data=05%7C01%7Cmnichols%40mpca.net%7Cae23c2d6cedf4987892508db5261c79f%7Cb0742aa378b24a8ba4c26df6b9965505%7C0%7C0%7C638194352140742351%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FjisM2RkSawvf0UITgVc91ahPvKt%2BvzMOvWOm6%2F8vVs%3D&reserved=0) that details codes and coverage
	+ We would also recommend checking out the MDHHS Temporary Extension to the Disaster Relief Policies for COVID-19 PHE Specific to Clinic Vaccine Administration Payments ([MMP 23-26](https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.michigan.gov%2Fmdhhs%2F-%2Fmedia%2FProject%2FWebsites%2Fmdhhs%2FAssistance-Programs%2FMedicaid-BPHASA%2F2023-Bulletins%2FFinal-Bulletin-MMP-23-26-Clinic.pdf%3Frev%3D173ab738a8a64dfc89c50f0bc3eb8b72%26hash%3D175EC729DB720619EF2CC523941C5FF9&data=05%7C01%7Cmnichols%40mpca.net%7Cae23c2d6cedf4987892508db5261c79f%7Cb0742aa378b24a8ba4c26df6b9965505%7C0%7C0%7C638194352140742351%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=qBLNqMvx1jmaeN9xGBNuDJQQVNj2a4U1bqa7vUJ3LRc%3D&reserved=0)) policy and the [CMS FQHC Center](https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cms.gov%2Fcenter%2Fprovider-type%2Ffederally-qualified-health-centers-fqhc-center&data=05%7C01%7Cmnichols%40mpca.net%7Cae23c2d6cedf4987892508db5261c79f%7Cb0742aa378b24a8ba4c26df6b9965505%7C0%7C0%7C638194352140742351%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=mmpn6eW9%2BHexUBS38i7S7Ih3atGz%2BdRy5V5G1rm3tLA%3D&reserved=0) webpage for details on Medicare

**Critical Points-COVID-19 Treatment**

* PHE ending will not affect EUAs for COVID-19 treatments
	+ Existing EUAs for treatment will remain in effect and the agency may continue to issue new EUAs
	+ Prescribing of COVID-19 treatments will continue as directed by the EUA of the product
* PHE ending will not affect the supply of COVID-19 treatments
	+ Treatments will still be a federal asset and ordered through MDHHS or HRSA
	+ Treatments will continue to be free of cost until commercialization is finalized
* The transition of COVID-19 treatments to commercial markets is being discussed at the federal level and HHS has stated it is likely to take place by the end of 2023

**What Health Centers Can Do**

**Right Now:**

* Continue vaccinating per CDC recommendations
* Continue prescribing COVID-19 therapeutics per EUA directives

**Resources & Links**

**Sub section**

* [CDC Interim Clinical Considerations-COVID Vaccines](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)
* [CDC COVID-19 Schedule Infographic](https://www.cdc.gov/vaccines/covid-19/downloads/COVID19-vaccination-recommendations-most-people.pdf)
* [CDC COVID Schedule Infographic-Immunocompromised](https://www.cdc.gov/vaccines/covid-19/downloads/COVID19-vaccination-recommendations-immunocompromised.pdf)
* [MDHHS COVID-19 Provider Webpage](https://www.michigan.gov/mdhhs/adult-child-serv/childrenfamilies/immunization/covid-19-vaccine-provider-guidance-and-educational-resources)
* [Side-by-Side Overview of Therapeutics Authorized or Approved for the Prevention of COVID-19 Infection or Treatment of Mild to Moderate COVID-19 (hhs.gov)](https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/side-by-side-overview.pdf)
* [Paxlovid | HHS/ASPR](https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid/Pages/default.aspx)
* [Lagevrio | HHS/ASPR](https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Lagevrio/Pages/default.aspx)
* [FAQ: What happens to EUAs When the PHE Ends (FDA)](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/faqs-what-happens-euas-when-public-health-emergency-ends)
* [Current State of the Transition of COVID-19 Medical Products to Commercial Markets\_Feb282023](https://aspr.hhs.gov/ASPRBlog/Pages/BlogDetailView.aspx?ItemID=451)